logo-loader
viewMyECheck

N4 Pharma heads down on disappointing data from Viagra reformulation study

The full set of results haven’t been made available yet, but N4 told investors that “it is clear” from the initial data that its reformulation did not have the desired effect on ED sufferers

man with erectile dysfunction
N4 will go away and look at the formulation of the drug and if there is anything they can change

N4 Pharma Plc (LON:N4P) shares halved at the opening bell on Monday as initial data from an early-stage trial of one of its lead drugs disappointed.

The AIM-quoted company has been trying to tweak the current formulation of sildenafil – commonly known as Viagra – to get the erectile dysfunction treatment to work more quickly and for a longer period of time.

N4 said it is yet to receive the full set of results, but “it is clear” from the data already received that its reformulation failed to meet the primary endpoints of the trial.

“This part of the process of drug reformulation is always going to be a challenge and whilst this preliminary data is clearly disappointing, we will need to see the full set of results expected around the end of August to understand the detailed implications for the formulation,” said chief executive Nigel Theobald.

“We will provide a further update once we have had a chance to review all the findings from the trial about the next steps we will take to reformulate the product.”

Theobald added that N4’s nuvec development program continues as planned with further results due later this year.

Shares collapsed by 56.5% to 10p.

Quick facts: MyECheck

Price: - -

PINK:MYEC
Market: PINK
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Dunnedin Ventures changes name of company to Kodiak Copper Corp

Dunnedin Ventures (CVE: DVI) CEO Claudia Tornquist joined Steve Darling from Proactive Vancouver to discuss the company changing their name to Kodiak Copper Corp with the ticker symbol KDK. Tornquist telling Proactive why the change and also if the COVID-19 pandemic has affected their...

12 hours, 54 minutes ago

2 min read